Is Aligos Therapeutics struggling financially?

Yes, by its own account. Aligos Therapeutics told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector: Biotech/Pharma
Market cap: $41.7M
Source filing: 10-Q 7 May 2026
Balance sheet: 30 Jun 2026

Cash runway

2months

If the burn speeds up

Empty by Aug 2026
3months

If it eases off

Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$30.4M

Cash burned over the last 12 months

$153.7M

What Aligos Therapeutics told the SEC

…results and costs related to the research and development of our pipeline; our recurring losses from operations and negative cash flows have raised substantial doubt regarding our ability to continue as a going concern; the timing of, and costs involved in, obtaining and maintaining regulatory approval for any of our current or future drug candidates, and any related restrictions or limitations;…

Aligos Therapeutics, Inc., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

11.0% share-count increase The company issued stock. Each share now owns 9.9% less of the business than a year ago, before any change in the price.
Cash burn is increasing It is spending 11% more cash per year than it was, so the runway above shortens even if nothing else changes.

Cash runway

The runway math

What Aligos Therapeutics told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt